ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "complement"

  • Abstract Number: 931 • 2018 ACR/ARHP Annual Meeting

    Patients with Seropositive Rheumatoid Arthritis Who Do Not Mount a CRP Response When They Have Synovitis Are Immunologically Distinct and Are Poorly Served By Current Management Strategies

    Thomas McDonnell1, Claire Bradford2, Divya Raj3, Coziana Ciurtin4, Elizabeth Jury2 and Jessica Manson5, 1Rayne Institute, University College London, London, United Kingdom, 2Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, 3Rheumatology, University College London Hospitals NHS Trust, London, United Kingdom, 4University College London, London, United Kingdom, 5University College London Hospitals NHS Trust, London, United Kingdom

    Background/Purpose: An atypical subgroup of patients with seropositive rheumatoid arthritis (RA) has been identified with confirmed synovitis but normal levels of the acute phase protein…
  • Abstract Number: 1017 • 2018 ACR/ARHP Annual Meeting

    Autoantigen Pentraxin-3 Is an Inflammatory Cytokine Storms Suppressor By Switching Monocytes Pyroptosis to Apoptosis in a Complement-Dependent Manner in Rheumatoid Arthritis

    Xuan Zhang1 and Xunyao Wu2, 1Rheumatology, Peking Union Medical College Hospital, Beijing, China, 2Peking Union Medical College Hospital, beijing, China

    Background/Purpose: A delayed diagnoses and therapy of ACPA (Anti cyclic citrullinated peptide antibody)-negative RA patients might be associated with effective serum biomarkers in clinic. Methods:…
  • Abstract Number: 1098 • 2018 ACR/ARHP Annual Meeting

    Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)

    Timothy B. Niewold1, Alexander Meves2, Julia S. Lehman3, Karin Popovic-Silwerfeldt4, Cristine Charlesworth5, Marie Wahren-Herlenius6, Elisabet Svenungsson7 and Vilija Oke8, 1Colton Center for Autoimmunity, New York University, New York, NY, 2Cancer Cenetr, Dermatology, Mayo Clinic, Rochester, MN, 3Pathology and Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, 4Department of Clinical Sciences, Dermatology Clinic, Danderyds Hospital,, Stockholm, Sweden, 5Mayo Clinic, Rochester, MN, 6Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 7Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 8Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden

    Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are autoimmune diseases. The histopathological pattern of skin involvement can be similar, i.e. interface dermatitis, but the…
  • Abstract Number: 1708 • 2018 ACR/ARHP Annual Meeting

    Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus

    Min-Hua Tseng1 and Jing-Long Huang2, 1Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 2Medicine, Chang-Gung University, Taoyuan city, Taiwan

    Background/Purpose: Although aberrant complement activation is involved in the pathogenesis of systemic lupus erythematosus (SLE), the role of complement regulatory proteins in disease activity of…
  • Abstract Number: 670 • 2017 ACR/ARHP Annual Meeting

    Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment

    Shudan Wang1, Ming Wu2, Luis Chiriboga3, Briana Zeck4 and H. Michael Belmont5, 1Department of Medicine, Division of Rheumatology, New York University School Medicine, New York City, NY, 2New York University School of Medicine, New York, NY, 3Pathology, New York University School Medicine, New York, NY, 4Pathology, New York University School Medicine, New York City, NY, 5Medicine, New York University School of Medicine, New York, NY

    Background/Purpose: LN is characterized by deposition of immune complexes in the kidney. Activation of the classical complement pathway by dsDNA is believed to play a…
  • Abstract Number: 1077 • 2017 ACR/ARHP Annual Meeting

    The Lectin Pathway of the Complement System Is Activated in Patients with Systemic Lupus Erythematosus

    Anne Troldborg1,2, Steffen Thiel3, Marten Trendelenburg4, Justa Friebus-Kardash5, Josephine Nehring5, Rudi Steffensen6, Søren Werner Karlskov Hansen7, Magdalena Janina Laska1, Bent Deleuran8, Jens Christian Jensenius1, Anne Voss9 and Kristian Stengaard-Pedersen10, 1Biomedicine, Aarhus University, Aarhus, Denmark, 2clinical medicine, Aarhus University, Aarhus, Denmark, 3Institute of Biomedicine, Aarhus University, Aarhus, DK, Aarhus, Denmark, 4Department of Biomedicine, Division of Internal Medicine, Basel, Switzerland, 5University Hospital Basel, Division of Internal Medicine, Basel, Switzerland, 6Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark, 7Department of Cancer and Inflammation Research, University of Souther Denmark, Odense, Denmark, 8Department of Biomedicine, Aarhus University, Aarhus, Denmark, 9Rheumatology, Odense University Hospital, Odense, Denmark, 10Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: The pathogenesis of Systemic Lupus Erythematosus (SLE) involves complement activation. It is well established that activation of complement through the classical pathway (CP) and…
  • Abstract Number: 1671 • 2017 ACR/ARHP Annual Meeting

    Complement C4 Gene Copy Number Variations Bestow Large Ranges of Serum C4 Protein Levels in Chinese Patients with Systemic Lupus Erythematosus (SLE) and Contribute to Organ and Cardiovascular Damages over Time

    Chi Chiu Mok1, Emily King2, Bi Zhou3, Gakit Yu4, Yee Ling Wu5 and CHACK-YUNG Yu6, 1Rheumatology, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Pediatrics, Nationwide Children's Hospital, Columbus, OH, 3Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 4Center for Molecular and Human Genetics, Nationwide Children's Hospital, Columbus, OH, 5Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, OH, 6Pediatrics, Ohio State Univ, Columbus, OH

    Background/Purpose: Human SLE is characterized by fluctuating serum levels of complement proteins. There are frequent copy number variations (CNVs) of complement C4A and C4B genes…
  • Abstract Number: 1842 • 2017 ACR/ARHP Annual Meeting

    Subsetting Systemic Lupus Erythematosus By Interferon Gene Signatures and Serologies (anti-dsDNA and Low Complement) Uncovers Significant Clinical Diversity

    Michelle Petri1, Steven Watts2, Richard Higgs2, MaryAnn Morgan-Cox2 and Matthew D Linnik3, 1Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 2Eli Lilly and Company, Indianapolis, IN, 3Immunology, Lilly Biotechnology Center, San Diego, CA

    Background/Purpose:   Personalized therapy in systemic lupus erythematosus (SLE) will require identifying SLE subsets that will benefit from different targeted therapies.  Belimumab, for example, has…
  • Abstract Number: 129 • 2017 Pediatric Rheumatology Symposium

    Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus

    Joyce Hui-Yuen1, Derren Barken2, John Conklin3, Tyler O'Malley4, Andrew Eichenfield5, Amy Starr6, Lisa F. Imundo7, Thierry Dervieux4 and Anca Askanase8, 1Cohen Children's Medical Center of New York, Lake Success, NY, 2Exagen Diagnostics, Vista, CA, 31261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 4Research and Development, Exagen Diagnostics, Vista, CA, 5Columbia University Medical Center, New York, NY, 6Pediatric Rheumatology, Columbia University Medical Center, New York, NY, 7Pediatrics, Columbia University Medical Center, New York, NY, 8Rheumatology, Columbia University Medical Center, New York, NY

    Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
  • Abstract Number: 149 • 2017 Pediatric Rheumatology Symposium

    Deficiency of Complement C4A or Low Copy Number of Total C4 Genes, HLA-DRB1*15 and HLA-DRB1*03 Are Strong Genetic Risk Factors for Pediatric SLE of European Descent

    Stacy Ardoin1, Pinar Ozge Avar Aydin2, Lai Hin Kimi Chan3, Katherine Lintner4, Yee Ling Wu5,6, Rabheh Aziz1, Anjali Patwardhan7,8, Evan Mulvihill1, Gakit Yu9, Bi Zhou10, Emeli Lundstrom11, Leonid Padyukov12, Kyla Driest13, Cagri Yildirim-Toruner13, Sharon Bout-Tabaku13, Charles Spencer14, Gloria Higgins1, Sampath Prahalad15, Hermine Brunner16 and Chack-Yung Yu10,17, 1Pediatrics and Rheumatology, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 2Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Pediatrics, Emory University School of Medicine, Atlanta, GA, 4Pediatrics, Nationwide Children's Hospital, Columbus, OH, 5The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 6Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, OH, 7Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 8Pediatric Rheumatology, Nationwide Children's Hospital, Columbia, MO, 9Center for Molecular and Human Genetics, Nationwide Children's Hospital, Columbus, OH, 10Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 11Rheumatology, Karolinska Institute, Stockholm, Switzerland, 12Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden, 13Rheumatology, Nationwide Children's Hospital, Columbus, OH, 14Rheumatology, Nationwide Childrens Hospital/OSU, Columbus, OH, 15Pediatrics, Emory Children's Center, Atlanta, GA, 16Rheumatology, PRCSG, Cincinnati, OH, 17Pediatrics, Ohio State Univ, Columbus, OH

    Background/Purpose:  A complete genetic deficiency of complement C4 almost always leads to the pathogenesis of systemic lupus erythematosus (SLE) with childhood onset, although its prevalence…
  • Abstract Number: 1751 • 2016 ACR/ARHP Annual Meeting

    Coagulation Pathway Function in Ischemia/Reperfusion Tissue Injury in Autoimmune Prone Mice

    Rachel C. Robbins1, Christopher Tracy2, Jess Edison1, Suzette Peng3 and Chantal Moratz4, 1Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, 2Walter Reed National Military Medical Center, Bethesda, MD, 3Food and Drug Administration, Silver Spring, MD, 4Uniformed Services University, Bethesda, MD

    Results: Tissue Factor Pathway Inhibitor (TFPI) and Anti-thrombin III (ATIII) resulted in reduction of tissue injury, as determined by histopathology scoring. However, TFPI was significantly…
  • Abstract Number: 2421 • 2016 ACR/ARHP Annual Meeting

    Cell-Bound Complement Activation Products Correlate with Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

    Joyce Hui-Yuen1, Derren Barken2, John Conklin3, Tyler O'Malley4, Andrew Eichenfield5, Amy Starr6, Lisa F. Imundo7, Thierry Dervieux8 and Anca D. Askanase9, 1North Shore-Long Island Jewish Health System, Lake Success, NY, 2Exagen Diagnostics, Inc., Vista, CA, 31261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 4Research and Development, Exagen Diagnostics, Vista, CA, 5Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, 6Pediatric Rheumatology, Columbia University Medical Center, New York, NY, 7Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, 8Research and Development, Exagen Diagnostics, Inc., Vista, CA, 9Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY

    Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
  • Abstract Number: 2797 • 2016 ACR/ARHP Annual Meeting

    Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus

    Daniel J Wallace1, Rosalind Ramsey-Goldman2, Anca D. Askanase3, Susan Manzi4, Joseph Ahearn5, Richard Furie6, Arthur Weinstein7, Chaim Putterman8, Elena Massarotti9, Christopher Collins10, Kenneth Kalunian11, Cristina Arriens12, Stuart L. Silverman13, Smitha Reddy14, Puja Chitkara15, Claudia Ibarra16, Derren Barken17, Roberta Alexander18, John Conklin19 and Thierry Dervieux20, 1Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 2FSM, Northwestern University, Chicago, IL, 3Medicine, Rheumatology, Columbia University Medical Center, New York, NY, 4Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, 5Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, 6North Shore University Hospital, Great Neck, NY, 7Rheumatology Section, Washington Hospital Center, Washington, DC, 8Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, 9Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, 10MedStar Washington Hospital Center, Washington, DC, 11Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, 12Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 13Cedars, Beverly Hills, CA, 14Arthritis Care and Research Center, Inc., Poway, CA, 15Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, 16Clinical Laboratory, Exagen Diagnostics, Vista, CA, 17Exagen Diagnostics, Vista, CA, 18Research & Development, Exagen Diagnostics, Vista, CA, 191261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 20Research and Development, Exagen Diagnostics, Vista, CA

    Background/Purpose: A panel of autoantibodies in combination with C4d-bound complement activation products (CB-CAPs, EC4d and BC4d) has been established as a sensitive and specific testing…
  • Abstract Number: 2856 • 2016 ACR/ARHP Annual Meeting

    Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms

    Yuko Sakuma1, Tatsuo Nagai2, Taku Yoshio3 and Shunsei Hirohata4, 1Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, 2Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, 3Jichi Medical University, Tochigi, Japan, 4Kitasato University School of Medicine, Sagamihara, Japan

    Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…
  • Abstract Number: 2958 • 2016 ACR/ARHP Annual Meeting

    Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden

    Christopher Sjöwall1, Thomas Mandl2 and Aladdin Mohammad3,4, 1Linköping University, Department of Clinical and Experimental Medicine Rheumatology/AIR, Linköping, Sweden, 2Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, 3Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Rheumatology, Lund, Sweden, Lund, Sweden, 4Addenbrooke’s Hospital, Vasculitis and Lupus Clinic, Cambridge, UK, Cambridge, United Kingdom

    Background/Purpose: Since first described by McDuffie et al. in 1973, hypocomplementemic urticarial vasculitis (HUV) syndrome has been recognized as a specific autoimmune disorder involving at…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology